Heidelberg Pharma AG: A Leader in Biopharmaceutical Innovation

Heidelberg Pharma AG, a prominent biopharmaceutical company based in Germany, continues to make significant strides in the healthcare sector, particularly in the development and commercialization of novel cancer therapies. The company, which operates under the health care sector and biotechnology industry, is dedicated to advancing research in pharmacology, drug metabolism, pharmacokinetics analysis, and molecular biology, with a focus on oncology and inflammatory diseases.

As of August 26, 2025, Heidelberg Pharma AG’s stock closed at 4.55 EUR on the Xetra stock exchange. The company’s market capitalization stands at 212,756,589 EUR, reflecting its robust presence in the biopharmaceutical landscape. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 5.36 EUR on June 5, 2025, and a low of 2.11 EUR on December 26, 2024.

Founded with an initial public offering on November 13, 2006, Heidelberg Pharma AG has consistently served patients and healthcare professionals in Germany. The company’s commitment to innovation is evident in its specialized focus on oncology and inflammatory diseases, areas that require cutting-edge research and development to improve patient outcomes.

Heidelberg Pharma AG’s efforts in pharmacology and molecular biology are crucial in the ongoing battle against cancer, as the company seeks to bring new and effective therapies to market. By leveraging advanced techniques in drug metabolism and pharmacokinetics analysis, the company aims to enhance the efficacy and safety of its therapeutic offerings.

For more information about Heidelberg Pharma AG and its initiatives, interested parties can visit the company’s website at www.heidelberg-pharma.com . As the company continues to grow and innovate, it remains a key player in the biopharmaceutical industry, dedicated to improving healthcare through scientific advancement.